Teva Canada’s Herzuma (biosimilar, trastuzumab) Receives Health Canada Approval for Multiple Cancer Indications

 Teva Canada’s Herzuma (biosimilar, trastuzumab) Receives Health Canada Approval for Multiple Cancer Indications

Teva Canada’s Herzuma (biosimilar, transtuzumab) Receives Health Canada Approval for Multiple Cancer Indications

Shots:

  • Health Canada has granted notice of compliance for Teva Canada’s Herzuma for the treatment of early breast cancer (EBC), metastatic breast cancer (MBC) and metastatic gastric cancer (MGC) in Canada
  • The Health Canada NOC is based on efficacy, safety, quality, immunogenicity, PK/PD data from non-clinical and clinical studies, demonstrating that Herzuma and Herceptin has high bio similarity in terms of purity, potency and safety for the three approved indications
  • Herzuma is a mAb biosimilar of the reference product, Herceptin targeting ECD of HER2 receptor and has received MFDS, EC and the FDA’s approval in Jan’2014, Feb’2018 and Dec’2018 respectively

Click here to­ read full press release/ article | Ref: Newswire Canada | Image: ImgBin

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post